Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Curaleaf Slumps Midday After Receiving FDA Warning Letter

Published 07/23/2019, 11:21 AM
Updated 07/23/2019, 03:06 PM
© Reuters.

Investing.com - Curaleaf slumped in midday trade Tuesday after receiving a warning letter from the Federal Drug Administration over its promotion of unapproved products containing cannabidiol (CBD).

The cannabis operator has 15 days to submit a written plan to address the violations.

Curaleaf (OTC:CURLF) fell 6.3%, while Aurora Cannabis (NYSE:ACB) slipped 1.5% and Canopy Growth (NYSE:CGC) was flat.

The FDA letter says the company’s products are unapproved drugs and the company has claimed on its website and social media accounts that its CBD products soothe chronic pain and relieve anxiety.

CBD has exploded in popularity as it lacks the psychoactive properties of THC. The FDA is still creating clearer guidelines for CBD, which it considers a drug.

Latest comments

FDA is only flexing what they still think they have a strong hold. CBD is absolutely nonsense as a drug. Think of who is running the show, a bunch of old folks with old ideas.
CBD is a plant based chemical or ingredient and cannot be considered a drug because it is from a plant that is grown from God putting it on this planet! The USA government actually put a patent on CBD in 1972. Hypocrites in the government are trying to stop it so big Pharma can still put out their dangerous drugs called opiates! All big Pharma companies making opioids should be stocked and close down completely! CBD can do everything in the body associated with pain I have experienced it’s superior pain relieving situation when I had right shoulder surgery after it and it totally took away the pain that post with every heartbeat! Get with the program US government you cannot have something patented by YOU in 1972 and now in 2019 change that. CBD should not be considered a drug at all!
pharma boys are worried
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.